查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1967310

Cas9核酸酶市場：按類型、形式、遞送方式、應用、最終用戶和治療領域分類－2026-2032年全球預測

Cas9 Nuclease Market by Type, Format, Delivery Method, Application, End User, Therapeutic Area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

Cas9核酸酶市場預計到2025年價值6.5619億美元，到2026年成長到7.1532億美元，到2032年達到12.3001億美元，年複合成長率為9.39%。

主要市場統計數據
基準年 2025 6.5619億美元
預計年份：2026年 7.1532億美元
預測年份 2032 123001億美元
複合年成長率 (%) 9.39%

本次演講將探討 Cas9 核酸酶技術在基因編輯、治療方法創新和重塑下一代基因組研究中的關鍵角色和發展歷程。

過去十年間，Cas9核酸酶已成為現代基因組編輯技術的基石，使研究人員能夠以前所未有的精準度靶向特定DNA序列。這種源自細菌免疫系統的突破性工具正在加速基礎研究、藥物開發和治療創新領域的發現步伐。隨著科學家不斷揭示Cas9的切割機制，它在基因工程領域推動突破的能力仍然無與倫比。

突破性的技術進步和策略轉變正在改變 Cas9 核酸酶市場的模式和研究前沿。

隨著Cas9核酸酶領域的日益成熟，新一輪創新浪潮正在重新定義研究人員和產業領導者的策略重點。高保真Cas9變異體的創新顯著減少了非預期基因組突變，增強了人們對其治療應用的信心。同時，失活Cas9融合體的出現，釋放精準表觀表觀基因編輯與轉錄調控的潛力，拓展了功能基因體學的視野。

分析美國新關稅對 Cas9 核酸酶的供應鏈、成本結構和全球研究合作的連鎖影響。

美國2025年實施的新關稅標誌著Cas9核酸酶供應鏈和成本結構的重大轉折點。試劑盒、試劑、質體載體、純化蛋白和核糖核蛋白複合物等通常從國際供應商採購的組件的到岸成本已進行調整，從而影響了整個採購預算。為此，各組織正在重新審視其籌資策略，以在控制成本的同時確保關鍵試劑的穩定供應。

本文提出了重要的細分見解，揭示了 Cas9 核酸酶在不同類型、形式、給藥方法和治療領域中的獨特用途。

對Cas9核酸酶細分市場的深入理解揭示了一個多維市場結構，涵蓋酶類型、製備形式、遞送方法、應用、最終用戶和治療重點領域。按類型分類，失活Cas9的存在使得標靶表觀基因編輯應用成為可能，而高保真Cas9變體對於最大限度減少脫靶事件至關重要。同時，切口型Cas9和野生型Cas9在需要單鏈或已建立的雙鏈的應用中繼續發揮重要作用。

本研究探討了美洲、歐洲、中東和非洲以及亞太地區的區域趨勢在塑造 Cas9 核酸酶的引入和發展的重要角色。

區域趨勢在Cas9核酸酶的廣泛應用過程中發揮著至關重要的作用，每個地區都展現出其獨特的優勢和考量。在美洲，健全的資金籌措機制和完善的研究基礎設施正在加速基因編輯技術的開發和商業化。領先的學術機構和生物技術集群持續進行創新應用的試點研究，為新型試劑和工具的開發者創造了競爭環境。

案例研究：領先的創新者和策略合作夥伴如何推動 Cas9 核酸酶技術開發和市場競爭力以取得突破性進展。

Cas9核酸酶的競爭格局由成熟的生命科學供應商和靈活的生物技術公司共同構成。領先的創新者不斷推出工程化變體和最佳化的遞送試劑，推動了一系列授權合約和策略夥伴關係的達成。工具供應商和製藥公司之間的合作研究正在加速基因編輯療法的臨床前開發，並凸顯了整個產業對轉化應用的重視。

為行業領導者提供策略建議，以最佳化 Cas9 核酸酶研究投資、推動創新並應對監管和市場變化。

產業領導者可以利用Cas9核酸酶的發展勢頭，採取兼顧創新與營運韌性的專注策略。酶變體和製劑的多樣化組合，能夠使研究項目在不斷變化的科學需求面前保持敏捷性。透過持續投資高保真度和niczese版本，同時維持對野生型和惰性Cas9的供應，其應用場景可從精確鹼基修飾擴展到轉錄調控。

詳細的調查方法，包括資料收集、檢驗過程和分析框架，為 Cas9 核酸酶市場情報報告提供支援。

本報告採用嚴謹的一手資料研究和全面的二手資料研究相結合的調查方法，以提供可靠的市場洞察。透過對分子生物學家、製程開發科學家和臨床研究主任的專家訪談，我們直接了解了新興趨勢和營運挑戰。這些定性研究結果與同行評審的出版物、專利申請和監管資訊披露進行了交叉檢驗，以確保其準確性和背景資訊。

結論性研究結果支持了 Cas9 核酸酶在基因編輯和治療創新中的應用策略重點和未來前景。

總而言之，Cas9核酸酶生態系統正經歷快速發展，這得益於增強特異性的工程化變體、提高安全性和有效性的多樣化遞送平台，以及拓展科學和臨床效用的新領域。美國關稅政策的變化正在促使供應鏈進行策略性調整，而美洲、歐洲、中東和非洲以及亞太地區的區域優勢則持續塑造全球擴散格局。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：Cas9核酸酶市場：依類型分類

  • 死亡 Cas9
  • 高保真Cas9
  • Nickzeze Cas9
  • 野生型 Cas9

第9章：Cas9核酸酶市場：依形式分類

  • 試劑盒和試劑
  • 質體載體
  • 純化蛋白
  • 核糖核蛋白複合物

第10章：Cas9核酸酶市場：依遞送方式分類

  • 非病毒載體
  • 身體的
  • 病毒載體

第11章：Cas9核酸酶市場：依應用分類

  • 低音編輯
  • 表觀基因編輯
  • 基因啟用設定
  • 基因敲入
  • 基因敲除
  • 基因抑制

第12章：Cas9核酸酶市場：依最終用戶分類

  • 學術和研究機構
  • 生物技術和製藥公司
  • CRO（受託研究機構）
  • 醫院和診所

第13章 Cas9 核酸酶市場：依治療領域分類

  • 血液學
  • 感染疾病
  • 代謝性疾病
  • 神經病學
  • 腫瘤學
  • 眼科

第14章：Cas9核酸酶市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：Cas9核酸酶市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：Cas9核酸酶市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國Cas9核酸酶市場

第18章：中國Cas9核酸酶市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Addgene, Inc.
  • Agilent Technologies, Inc.
  • Applied Biological Materials Inc.
  • Creative Biolabs
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • GeneON GmbH
  • GenScript Biotech Corporation
  • Hoelzel Biotech GmbH
  • Horizon Discovery Group by Revvity, Inc.
  • Intellia Therapeutics, Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • New England Biolabs, Inc.
  • Novatein Biosciences Inc.
  • Novoprotein Scientific, Inc.
  • OZ Biosciences SAS
  • Promega Corporation
  • SBS Genetech
  • Synthego Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-0A380695180E

The Cas9 Nuclease Market was valued at USD 656.19 million in 2025 and is projected to grow to USD 715.32 million in 2026, with a CAGR of 9.39%, reaching USD 1,230.01 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 656.19 million
Estimated Year [2026] USD 715.32 million
Forecast Year [2032] USD 1,230.01 million
CAGR (%) 9.39%

Discover the pivotal role and evolution of Cas9 nuclease technology reshaping gene editing, therapeutic innovation, and next-generation genomic research

The past decade has witnessed Cas9 nuclease emerge as a cornerstone of modern genome editing, enabling researchers to target specific DNA sequences with unprecedented precision. This transformative tool, derived from bacterial immune systems, has accelerated the pace of discovery across basic research, drug development, and therapeutic innovation. As scientists continue to refine the mechanism of Cas9-mediated cleavage, its capacity to drive breakthroughs in genetic engineering remains unparalleled.

In parallel, advancements in enzyme engineering have given rise to specialized variants that bolster specificity and reduce off-target effects. The integration of Cas9 into diverse delivery platforms has broadened the scope of applications, spanning from in vitro gene function studies to in vivo therapeutic interventions. Such technological progression has attracted significant interest across academic laboratories, biotechnology firms, and clinical research organizations.

This executive summary synthesizes the key developments shaping the Cas9 nuclease landscape. By examining dynamic shifts in technology, regulatory influences, segmentation trends, regional drivers, and leading market participants, this report delivers a clear view of strategic opportunities. Readers will gain a concise yet thorough understanding of the critical factors propelling the evolution and adoption of Cas9 nuclease solutions.

Unveiling the groundbreaking technological advances and strategic pivots transforming the Cas9 nuclease market landscape and research frontiers

As the Cas9 nuclease field matures, a new wave of transformative shifts is redefining strategic priorities for researchers and industry leaders alike. Innovations in high fidelity Cas9 variants have markedly reduced unintended genome alterations, catalyzing confidence in therapeutic applications. Simultaneously, the emergence of dead Cas9 fusions has unlocked the potential for precise epigenome editing and transcriptional regulation, expanding the horizons of functional genomics.

Moreover, the adoption of nickase Cas9 formats, which introduce single-strand breaks, has provided an additional layer of control for refined editing outcomes. Researchers are increasingly leveraging purified proteins and ribonucleoprotein complexes to achieve transient, high-efficiency editing while mitigating long-term cellular exposure. At the same time, plasmid vectors and kits & reagents remain foundational for streamlined laboratory workflows.

Delivery methods are also undergoing a paradigm shift, with non-viral and physical techniques offering alternatives to traditional viral vectors. These approaches promise enhanced safety profiles and rapid deployment. In parallel, the application spectrum is broadening from gene knockout experiments to sophisticated base editing and gene activation platforms. Together, these advances are charting a course toward more reliable, flexible, and scalable Cas9 nuclease solutions that will shape the next chapter of genomic science.

Analyzing the cascading effects of new United States tariffs on Cas9 nuclease supply chains, cost structures, and global research collaborations

The introduction of new United States tariffs in 2025 has created a notable inflection point for Cas9 nuclease supply chains and cost structures. Components such as kits & reagents, plasmid vectors, purified proteins, and ribonucleoprotein complexes, which are often sourced from international suppliers, have seen adjustments in landed costs that ripple across procurement budgets. In response, organizations are reassessing their sourcing strategies to balance cost containment with uninterrupted access to critical reagents.

These tariff adjustments have also influenced collaborative research, as cross-border partnerships must navigate evolving import duties on physical and non-viral delivery kits alongside viral vector materials. Contract research organizations and biotechnology firms have initiated localized manufacturing and distribution pathways to mitigate financial exposure. Consequently, supply chain resilience has become a central consideration, prompting investment in regional production hubs and strategic vendor alliances.

Looking ahead, stakeholders are adapting to this new regulatory reality by diversifying supplier portfolios and exploring alternative formats that can reduce dependency on tariff-impacted goods. This proactive stance supports continuity in Cas9 nuclease projects, safeguards research timelines, and maintains momentum in therapeutic discovery and development.

Illustrating critical segmentation insights revealing distinct Cas9 nuclease applications across diverse types, formats, delivery methods, and therapeutic domains

A nuanced understanding of Cas9 nuclease segmentation reveals the market's multi-dimensional landscape across enzyme types, preparation formats, delivery methods, applications, end users, and therapeutic focus areas. Based on Type, the presence of Dead Cas9 has unlocked targeted epigenome editing applications while High Fidelity Cas9 variants have become indispensable for minimizing off-target events. Meanwhile, Nickase Cas9 and Wild Type Cas9 maintain their roles in applications demanding either single-strand breaks or established double-strand cleavage.

Based on Format, laboratory workflows leverage Kits & Reagents for streamlined protocols, Plasmid Vectors for flexible gene construct delivery, Purified Proteins for direct editing with transient exposure, and Ribonucleoprotein Complexes for rapid and precise targeting. In terms of Delivery Method, Non-Viral Vectors, Physical techniques such as electroporation, and Viral Vectors each offer distinct trade-offs in efficiency, safety, and scalability.

Based on Application, the field extends from base editing, which facilitates single nucleotide modifications, to epigenome editing for transcriptional control, as well as gene activation, gene knockin, gene knockout, and gene repression. Based on End User, Academic & Research Institutes continue to drive foundational studies, Biotechnology & Pharmaceutical Companies prioritize therapeutic pipelines, Contract Research Organizations enable large-scale screening and custom services, and Hospitals & Clinics explore clinical and diagnostic adaptations.

Based on Therapeutic Area, Hematology has seen early clinical translation, Infectious Diseases leverage gene disruption strategies, Metabolic Disorders target corrective editing, Neurology explores central nervous system interventions, Oncology focuses on engineered cell therapies, and Ophthalmology pioneers sight-restoring approaches. Through this integrated lens, stakeholders can align their strategies with the most compelling segments and emerging opportunities.

Examining the pivotal role of regional dynamics across Americas, Europe, Middle East & Africa, and Asia-Pacific in shaping Cas9 nuclease adoption and growth

Regional dynamics play a pivotal role in shaping Cas9 nuclease adoption, with each geography exhibiting unique strengths and considerations. In the Americas, robust funding mechanisms and well-established research infrastructure have accelerated the development and commercialization of gene editing technologies. Leading academic centers and biotechnology clusters continue to pilot innovative applications, fostering a competitive environment for new reagent and tool developers.

In Europe, Middle East & Africa, harmonized regulatory frameworks and pan-European research initiatives have cultivated a collaborative ecosystem. Cross-border consortia and funding programs support translational research, bolstering the region's capacity to integrate Cas9 nuclease platforms into precision medicine strategies. Meanwhile, a growing network of clinical centers in the Middle East is exploring gene editing's potential to address region-specific genetic disorders.

The Asia-Pacific region stands out for its manufacturing prowess and rapidly expanding biotech sectors. Local production of kits, vectors, and proteins has reduced lead times and increased cost competitiveness. Simultaneously, emerging markets in Asia are fostering academic and industrial partnerships to accelerate access to Cas9 nuclease technologies, positioning the region as a dynamic contributor to global innovation.

Highlighting leading innovators and strategic partnerships driving breakthroughs in Cas9 nuclease technology development and market competitiveness

The competitive landscape of Cas9 nuclease is defined by a combination of established life science suppliers and agile biotechnology firms. Leading innovators have introduced engineered variants and optimized delivery reagents, spurring a wave of licensing agreements and strategic partnerships. Collaborative research efforts between tool providers and pharmaceutical companies have accelerated preclinical development of gene editing therapeutics, underscoring an industry-wide commitment to translational impact.

At the same time, new entrants are differentiating through proprietary protein engineering approaches and end-to-end service models. These companies offer integrated solutions spanning enzyme production, custom construct design, and hands-on technical support. In parallel, specialized contract research organizations are deepening their expertise in pipeline validation, enabling seamless progression from bench to clinic.

This dynamic environment is further characterized by cross-sector alliances, where academic spin-offs team up with manufacturing partners to scale production of high-fidelity variants and clinically relevant delivery systems. As these collaborations mature, they are expected to enhance supply chain robustness, expand application portfolios, and drive down the barriers to entry for emerging therapeutic modalities.

Strategic recommendations empowering industry leaders to optimize Cas9 nuclease research investments, drive innovation, and navigate regulatory and market shifts

Industry leaders can capitalize on Cas9 nuclease momentum by pursuing targeted strategies that balance innovation with operational resilience. Diversifying the portfolio of enzyme variants and preparation formats ensures that research programs remain nimble in the face of evolving scientific needs. Investing in high-fidelity and nickase versions while retaining access to Wild Type and dead Cas9 expands use cases from precise base corrections to transcriptional regulation.

To mitigate supply chain risks, organizations should explore regional manufacturing partnerships and develop contingency sourcing plans for kits, plasmid vectors, purified proteins, and ribonucleoprotein complexes. Simultaneously, aligning delivery strategies with therapeutic objectives-choosing between non-viral, physical, or viral methods-will enhance the likelihood of clinical translation.

Engaging regulatory bodies early and establishing cooperative research frameworks with academic and contract research partners can streamline development pathways. Finally, focusing on high-growth therapeutic areas such as neurology, oncology, and ophthalmology will position stakeholders at the forefront of the next wave of gene editing breakthroughs.

Detailed methodology outlining data collection, validation processes, and analytical frameworks underpinning the Cas9 nuclease market intelligence report

This report's methodology combines rigorous primary research with comprehensive secondary data analysis to deliver robust market intelligence. Expert interviews with molecular biologists, process development scientists, and clinical research leads provided first-hand insights into emerging trends and operational challenges. These qualitative findings were cross-verified against peer-reviewed publications, patent filings, and regulatory disclosures to ensure accuracy and context.

Segmentation analysis was conducted across enzyme Type, including Dead Cas9, High Fidelity Cas9, Nickase Cas9, and Wild Type Cas9; Format variations spanning Kits & Reagents, Plasmid Vectors, Purified Proteins, and Ribonucleoprotein Complexes; Delivery Methods such as Non-Viral Vectors, Physical, and Viral Vectors; Applications ranging from Base Editing to Gene Repression; End Users comprising Academic & Research Institutes, Biotechnology & Pharmaceutical Companies, Contract Research Organizations, and Hospitals & Clinics; and Therapeutic Areas including Hematology, Infectious Diseases, Metabolic Disorders, Neurology, Oncology, and Ophthalmology.

Regional assessments encompassed the Americas, Europe, Middle East & Africa, and Asia-Pacific to capture geographic drivers. Market participant profiling and competitive mapping were informed by company-released data, strategic partnership announcements, and patent landscapes. Throughout the process, data triangulation and validation steps were employed to maintain integrity and relevance.

Concluding insights reinforcing strategic priorities and future outlook for Cas9 nuclease applications in gene editing and therapeutic innovation

In summary, the Cas9 nuclease ecosystem is advancing at a rapid pace, driven by engineered variants that enhance specificity, diverse delivery platforms that improve safety and efficacy, and new applications that extend its scientific and clinical utility. Tariff changes in the United States have prompted strategic supply chain adjustments, while regional strengths in the Americas, Europe, Middle East & Africa, and Asia-Pacific continue to shape global adoption patterns.

Segmentation insights underscore the importance of aligning enzyme type, format selection, delivery approach, application focus, end user needs, and therapeutic area priorities. Leading companies are forging partnerships and expanding capabilities to meet this complexity, while actionable recommendations highlight the value of diversified portfolios, regulatory engagement, and targeted investments in high-impact research areas.

Together, these findings present a comprehensive view of the factors defining the current and future state of Cas9 nuclease technologies, equipping stakeholders with the intelligence needed to make informed strategic decisions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cas9 Nuclease Market, by Type

  • 8.1. Dead Cas9
  • 8.2. High Fidelity Cas9
  • 8.3. Nickase Cas9
  • 8.4. Wild Type Cas9

9. Cas9 Nuclease Market, by Format

  • 9.1. Kits & Reagents
  • 9.2. Plasmid Vectors
  • 9.3. Purified Proteins
  • 9.4. Ribonucleoprotein Complexes

10. Cas9 Nuclease Market, by Delivery Method

  • 10.1. Non-Viral Vectors
  • 10.2. Physical
  • 10.3. Viral Vectors

11. Cas9 Nuclease Market, by Application

  • 11.1. Base Editing
  • 11.2. Epigenome Editing
  • 11.3. Gene Activation
  • 11.4. Gene Knockin
  • 11.5. Gene Knockout
  • 11.6. Gene Repression

12. Cas9 Nuclease Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Biotechnology & Pharmaceutical Companies
  • 12.3. Contract Research Organizations
  • 12.4. Hospitals & Clinics

13. Cas9 Nuclease Market, by Therapeutic Area

  • 13.1. Hematology
  • 13.2. Infectious Diseases
  • 13.3. Metabolic Disorders
  • 13.4. Neurology
  • 13.5. Oncology
  • 13.6. Ophthalmology

14. Cas9 Nuclease Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cas9 Nuclease Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cas9 Nuclease Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cas9 Nuclease Market

18. China Cas9 Nuclease Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Addgene, Inc.
  • 19.6. Agilent Technologies, Inc.
  • 19.7. Applied Biological Materials Inc.
  • 19.8. Creative Biolabs
  • 19.9. CRISPR Therapeutics AG
  • 19.10. Editas Medicine, Inc.
  • 19.11. GeneON GmbH
  • 19.12. GenScript Biotech Corporation
  • 19.13. Hoelzel Biotech GmbH
  • 19.14. Horizon Discovery Group by Revvity, Inc.
  • 19.15. Intellia Therapeutics, Inc.
  • 19.16. Lonza Group Ltd.
  • 19.17. Merck KGaA
  • 19.18. New England Biolabs, Inc.
  • 19.19. Novatein Biosciences Inc.
  • 19.20. Novoprotein Scientific, Inc.
  • 19.21. OZ Biosciences SAS
  • 19.22. Promega Corporation
  • 19.23. SBS Genetech
  • 19.24. Synthego Corporation
  • 19.25. Takara Bio Inc.
  • 19.26. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CAS9 NUCLEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CAS9 NUCLEASE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CAS9 NUCLEASE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CAS9 NUCLEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CAS9 NUCLEASE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CAS9 NUCLEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY DEAD CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY DEAD CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY DEAD CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HIGH FIDELITY CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HIGH FIDELITY CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HIGH FIDELITY CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NICKASE CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NICKASE CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NICKASE CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY WILD TYPE CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY WILD TYPE CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY WILD TYPE CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PLASMID VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PLASMID VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PLASMID VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PURIFIED PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PURIFIED PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PURIFIED PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY RIBONUCLEOPROTEIN COMPLEXES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY RIBONUCLEOPROTEIN COMPLEXES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY RIBONUCLEOPROTEIN COMPLEXES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NON-VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PHYSICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PHYSICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PHYSICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY BASE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY EPIGENOME EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY EPIGENOME EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY EPIGENOME EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE ACTIVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE ACTIVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE ACTIVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE KNOCKIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE KNOCKIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE KNOCKIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE KNOCKOUT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE KNOCKOUT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE KNOCKOUT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE REPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE REPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE REPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. GCC CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GCC CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 157. GCC CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 158. GCC CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 175. G7 CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. G7 CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. G7 CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 178. G7 CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 179. G7 CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. G7 CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. G7 CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 182. NATO CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. NATO CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NATO CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 185. NATO CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 186. NATO CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. NATO CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. NATO CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES CAS9 NUCLEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA CAS9 NUCLEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)